Lipocine (LPCN) Stock News
$LPCN · NASDAQ · 1 stories in 30 daysBORSA has published 1 story on Lipocine (LPCN) in the past 30 days. BORSA’s news read on LPCN is bullish at 69/100, −1 over 24 hours, based on 1 company event over the past 30 days. LPCN last closed at $1.69 on Oct 14, down 23.18% over five sessions and down 22.65% over the past month. Lipocine’s next earnings report is scheduled for Thursday, Nov 5.
The wire on $LPCN
newest first · updated · direct subject stories onlyLipocine's TLANDO receives Health Canada approval for testosterone replacement therapy
Health Canada approved TLANDO (testosterone undecanoate) capsules for testosterone replacement therapy in adult males with hypogonadism. Licensing partner Verity Pharma holds exclusive North American rights and plans Canadian launch by end of 2026. Lipocine sees opportunity in a market with over 700,000 annual TRT prescriptions, where oral options without dose titration are limited.
bullish 80 · impact 60